linjc16/ctgov huggingface dataset:
Internal Carotid Artery Blood Flow in Pediatric Moyamoya Patients

Study Overview
=================
Brief Summary
-----------------
Little is known about how general anesthesia-induced decrease in cerebral blood flow in pediatric moyamoya pateints. We investigated this question in patients undergoing moyamoya surgery, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.

Official Title
-----------------
A Study on Internal Carotid Artery Blood Flow Velocity in Children With Moyamoya Disease Undergoing Surgery: a Prospective Observational Study

Conditions
-----------------
Carotid Artery, Internal

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients undergoing encephaloduroarteriosynangiosis surgery for moyamoya disease Exclusion Criteria: cutaneous lesion on the neck

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Internal carotid artery blood flow velocity | ultrasound assessment of internal carotid artery blood flow velocity | from anesthetic induction to end of surgery, an average of 5 hours |
Observational, Prospective, Single-center Study: Should Body Mass Index (BMI) be Added to the Scoring Criteria of Hepatic Critically Ill Patients in Intensive Care Unit??

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the hypothesis of poor clinical outcomes in critically ill patients that are having abnormal BMI.

Detailed Description
-----------------
All demographic data will be obtained including the patients' age, sex, body mass index (BMI) & categorized into; BMI < 18.5Kg/m2 = underweight, BMI between 18.5-24.9Kg/m2 = normal weight, while BMI between 25-29.9Kg/m2 = overweight & obese = BMI ≥ 30Kg/m2, associated co-morbidities (diabetes mellitus, hypertension, chronic renal failure, cancer& chronic liver disease), the cause of admission to ICU, Sequential Organ Failure Assessment (SOFA), nutritional risk screening (NRS) on admission & discharge, prior cardiac arrest, previous ICU admission within 6months, nosocomial infection, organ failure e.g. cardiovascular, respiratory, renal & organic support requirement e.g. hemodynamic support, mechanical ventilation, renal replacement therapy (RRT).

Official Title
-----------------
Observational, Prospective, Single-center Study: Should Body Mass Index (BMI) be Added to the Scoring Criteria of Hepatic Critically Ill Patients in Intensive Care Unit??

Conditions
-----------------
ICU Stay & Mortality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are admitted to the intensive care unit of National Hepatology & Tropical Medicine Research Institute (NHTMRI) for medical & surgical indications during the period from February 2018 to December 2020. Exclusion Criteria: Patients will be excluded if they have stayed in ICU ≤24 hours and underweight (BMI<18.5).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU stay | Length of ICU stay in days | average 2 - 4 weeks | 
| Mortality | ICU Mortality in days | average 2-4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the need for mechanical ventilation | notice & register the need for & type of mechanical ventilation; invasive or non invasive & days of ventilation | during ICU stay 2-4 weeks | 
| Duration of mechanical ventilation | Duration in days | 1-4 weeks | 
| the need for pharmacological support | notice & register the need for drugs to support the hemodynamics | 1-4 weeks | 
| occurrence of nosocomial infection | site of nosocomial infection | 2-28 days | 
| Hospital stay | Length of hospital stay | average 2-28days | 
| Hospital mortality | mortality | average 28 days |
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Study Overview
=================
Brief Summary
-----------------
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of slow onset acute asthma , namely three AMP provocation tests performed on one day

Official Title
-----------------
A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementary Value of the Budesonide Component Within Symbicort When Tested in a Model of Slow Onset Acute Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: budesonide/formoterol Turbuhaler
* Drug: formoterol Turbuhaler
* Drug: salbutamol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: asthma diagnosis according to ATS criteria, lung function (FEV1) above 60% of predicted, AMP-PC20 below 160 mg/ml with a documented fall in FEV1 of 30% in this provocation test Exclusion Criteria: having smoked > 10 Pack-years, hypersensitivity to one of the study drugs, significant co-morbidity, pregnancy or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: budesonide/formoterol Turbuhaler|nan|
|Drug: formoterol Turbuhaler|nan|
|Drug: salbutamol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The decrease in lung function (FEV1) after the third AMP provocation test. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in lung function (FEV1) after the second AMP provocation test, |  |  | 
| lung function and Borg Score over the test day, |  |  | 
| increase in FEV1 at three minutes after study drug inhalation, |  |  | 
| time course of recovery from the AMP-induced decrease in lung function |  |  |
Use of an Ocular Telemetry Sensor in Diamox Treated Patients

Study Overview
=================
Brief Summary
-----------------
A soft contact lens integrating a Sensor is placed on subjects with high intraocular pressure (IOP) after administration of an IOP-lowering drug to investigate the device's capacity to detect the induced IOP reduction.

Official Title
-----------------
Detection of IOP Fluctuation With SENSIMED Triggerfish in Patients With Glaucoma or Ocular Hypertension Treated With Diamox

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Device: SENSIMED Triggerfish


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of glaucoma or ocular hypertension IOP of ≥ 15 mmHg. Patients of either gender. Older than 18 years. Patients who accept signing an informed consent approved by the Ethics Committee. Exclusion Criteria: Patients not able to understand the nature of the research Patients under tutorship Corneal abnormalities in both eyes Subjects with contraindications for wearing contact lenses History of ocular surgery within the last 3 months Known hypersensitivity to Diamox® or to any of its excipients Pregnancy and lactation Simultaneous participation in other clinical research Patients with evidence of ocular infection or inflammation History of renal or hepatic impairment, hypokalemia and hyponatremia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Glaucoma or ocular hypertension patients<br> | Device: SENSIMED Triggerfish<br>* 2-hour continuous IOP monitoring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of IOP reduction 2 hours after Diamox administration |  | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma and ocular hypertension patients
Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with previous malignancies have increasingly been accepted for renal transplantation. However, post-transplant malignancy risk and survival rates of these patients are unknown. Our aim was to assess if previous malignancies pose an unnecessarily high risk of post-transplant malignant tumours and if the organs as a resource are too limited for investment in this patient group.

Official Title
-----------------
Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer

Conditions
-----------------
Neoplasms, Kidney Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Kidney transplanted patients from January 1982 through December 2013 with or without a pre transplant cancer. Exclusion Criteria: Simultaneous kidney+pancreas transplantation. Islet cell transplanted patients Undiagnosed malignancies at the time of transplantation Death within a week after transplantation First transplantation at another hospital

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| KTx Uppsala<br>Patients who have received a kidney transplant in Uppsala. | |
| KTx Europe<br>Patients who have received a kidney transplant in Uppsala. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of post-transplant cancer |  | Up to 33 years starting in January 1982. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient survival |  | Up to 33 years starting in January 1982. | 
| Cancer-induced mortality |  | Up to 33 years starting in January 1982. |
Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

Official Title
-----------------
Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: acamprosate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic Parkinson's disease Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist) Able and willing to complete Rating Scales Presence of one or more compulsive behavior based on responses to Rating Scales (defined as >5 on the SOGS; >17 on the YBOCS-SV and YBOCS-CUV; >1.7 on the SCS for women and >2.1 on the SCS for men; >15 on the YBOCS-BE, >5.5 on the CQ). Written informed consent Inclusion criteria (controls): No significant psychiatric disease Able and willing to complete Rating Scales Written informed consent Exclusion Criteria: No anticipated need for adjustment of medications for Parkinson's disease Current participation in another clinical study History of unstable psychiatric disease (as determined by the Principal Investigator) Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: acamprosate|333 mg 2 tabs tid|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and efficacy compared to baseline scores |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline assessment tools used in the study |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, impulse control behaviors, dopa-dysregulation
Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program.

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical effectiveness of this screening program in preventing pre-eclampsia.

Detailed Description
-----------------
The incidence of pre-eclampsia is about 2-8%, it is a leading cause of maternal and perinatal mortality and morbidity. Both ACOG (American Congress of Obstetricians and Gynecologists) and NICE (National Institute for Health and Clinical Excellence) guideline advocate the use of traditional screening method, which uses demographic characters and medical history to identify high risk women. This method detects only 35-40% of pre-eclampsia women. Study has shown that combination of maternal factors and biomarkers (uterine artery pulsatility index, placenta growth factor, PlGF; pregnancy associated plasma protein-A, PAPP-A) improves the detection rate. In Taiwan, the prevalence of pre-eclampsia is about 1.21%. The incidence of pre-eclampsia is correlated with maternal age, with a relative risk of 5.13-fold in women aged 40 and above. Marrying late predisposes these women at high risk of developing pre-eclampsia. Our institution will be implementing first-trimester screening program starting from April 2019, this study aims to evaluate the clinical effectiveness of this screening program in preventing pre-eclampsia.

Official Title
-----------------
Far Eastern Memorial Hospital

Conditions
-----------------
Pre-eclampsia

Intervention / Treatment
-----------------
* Other: pre-eclampsia screening program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Women who are 20 years of age or older with singleton pregnancy between 11 to 13 + 6 weeks and received first trimester pre-eclampsia screening test in this institution. Exclusion Criteria: Women who are not regularly inspected or not receiving prenatal care in this institution. Women who received first trimester pre-eclampsia screening test at other institution

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The sensitivity and specificity of this screening program to detect preeclampsia |  | 5 years |
The Practical Use of Transthoracic Echocardiography for Obtaining an Optimal Depth of Internal Jugular Venous Catheters in Infants

Study Overview
=================
Brief Summary
-----------------
To test if transthoracic echocardiography is useful for correct positioning of central venous catheters in infants with congenital heart disease

Detailed Description
-----------------
Patients scheduled for surgery for congenital heart disease younger than 12 months were studied. Following successful catheter insertion, the insertion depth was determined using transthoracic echocardiography. The long axis or short axis images were used.Chest X-ray images were taken postoperatively and distances from the tip to the carina level were measured.

Conditions
-----------------
Insertion Depth of Central Venous Catheter

Intervention / Treatment
-----------------
* Procedure: transthoracic echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: scheduled for surgery under general anesthesia Exclusion Criteria: anomaly of the internal jugular vein thrombus in the internal jugular vein

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: transthoracic echocardiography<br> | Procedure: transthoracic echocardiography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the distance between the catheter tip and the carina |  | After opearation (about 4-6 hour after insertion of the catheter) |
Alleviant ALLAY-HF Study

Study Overview
=================
Brief Summary
-----------------
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

Official Title
-----------------
Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: Alleviant ALV1 System
* Other: Sham-Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic HFpEF/HFmrEF with LVEF greater than or equal to 40% NYHA Class II, III or ambulatory IV Exercise right heart catheterization* Elevated left atrial pressure during exercise right heart catheterization (greater than or equal to 25 mmHg) Exercise PVR < 1.8 WU Ongoing stable GDMT Exclusion Criteria: Advanced heart failure Presence of a pacemaker Evidence of right heart dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure. | Device: Alleviant ALV1 System<br>* Creation of interatrial shunt<br>|
| Sham Comparator: Control<br>Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein. | Other: Sham-Control<br>* Cardiac imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite Primary Endpoint | The primary endpoint is a composite of mortality, heart failure events and quality of life based on Kansas City Cardiomyopathy Questionnaire (KCCQ) calculated at 12 months. KCCQ responses are provided along a rating scale from 0-100 with a higher score indicating better health. | 12-month |
A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
This is a study to assess the safety, efficacy, and tolerability of MK0859 in patients with primary hypercholesterolemia (large amounts of cholesterol in the blood) or mixed hyperlipidemia (high levels of LDL cholesterol, triglycerides, and low levels of HDL cholesterol in blood) This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions
-----------------
Hypercholesterolemia, Hyperlipidemia

Intervention / Treatment
-----------------
* Drug: MK0859


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is between 18 and 75 years of age Patient can be on a stable diet for the study Patient has a stable weight for more then 6 weeks before the study and has not participated in a weight loss program Exclusion Criteria: Patient has chronic heart failure or a history of heart disease Patient has blood, digestive, or central nervous system disorders Patient is pregnant or nursing Patient is HIV positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0859|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |